You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.
SBC: Shift Pharmaceuticals Holdings, Inc. Topic: 106Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).
SBC: MAKSCIENTIFIC Topic: NIDAOTHER PROJECT INFORMATION – Unit 7 – Project Summary/Abstract This project addresses the growing need for medications for cannabis use disorder (CUD) which, in the absence of approved medications, is a major focus of NIDA’s mission. Currently available cannabinergic-based treatments for CUD include the directly acting CB1 agonists, e.g., Δ9-THC or nabilone, which have been reported to reduc ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Field Instrument for Assessment of Arsenic Exposure
SBC: GINER INC Topic: RProject Summary Human exposure to toxic heavy metals existing in drinking water, food, and the environment is an area of increasing national and international concern. Heavy metals are significant environmental pollutants because they tend to persist, bioaccumulate and can result in serious adverse acute or chronic health effects after ingested or inhaled. Traditionally, trace metals are measured ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections
SBC: Rational Vaccines, Inc. Topic: NIAIDPROJECT SUMMARY: Herpes Simplex Virus (HSV) infections are common, infecting more than half of the world’s population. While most cases of genital herpes are caused by HSV type 2 (HSV-2), it is estimated that more than 150 million people aged 15-49 have genital HSV type 1 (HSV-1) infections. Although several vaccines have been evaluated for preventing/treating HSV infections, none have received ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical validation of small molecule immunomodulators for the treatment of Crohn's disease
SBC: PROMAKHOS THERAPEUTICS INC Topic: 300Project Summary Crohn’s disease is a debilitating and chronic inflammatory disorder of the gastrointestinal tract characterized by aberrant healing and intestinal stricturing. In the US, rt500,000 patients suffer from Crohn’s disease and over 30,000 patients are newly diagnosed each year. No curative treatments exist. Instead, current treatments focus on managing symptoms and reducing the occu ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Improved Patient Reported Outcomes (iPRO)-Sleep Diary: A Tool to Improve Sleep Assessment in Clinical Trials
SBC: D-PRIME LLC Topic: NHLBIAbstract Insomnia is a highly prevalent condition that significantly degrades the quality of life and health of millions of patients. By diagnostic definition, insomnia is a disease characterized by self-reported subjective criteria, thus therapeutic developers targeting insomnia typically evaluate their treatment’s efficacy based on patient reported outcomes in the form of sleep diaries. A crit ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Improved optimization of covalent ligands using a novel implementation of quantum mechanics suitable for large ligand/protein systems.
SBC: QUANTUM SIMULATION TECHNOLOGIES INC Topic: 400Project Summary The value of computational chemistry to commercial drug discovery is now well-established. Virtual screening (including molecular docking) now jumpstarts most discovery efforts. Tools such as molecular dynamics and free energy perturbation are increasingly used to inform the later stages of lead refinement. The growing importance of computational structure-based methods has influen ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Consumer-Therapist-Connector: Increasing Access to Quality Behavioral Healthcare
SBC: OUTCOME REFERRALS INC Topic: 104ABSTRACT The United States is experiencing a major mental health crisis. Per recent reports in the New York Times and The Washington Post, the gap between need and access to behavioral health services is rapidly increasing. There is an urgent need to solve both the access and quality problems with behavioral healthcare. With COVID and other stressors, 76% of surveyed employees are reporting at lea ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.
SBC: Antiger Therapeutics Inc. Topic: NIAIDPROJECT SUMMARY/ABSTRACT The mission of Antiger Therapeutics Inc. is to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects. Antibody-mediated rejection (AMR) is a leading cause of graft loss, with over 3000 new cases per year in the United States and estimated market size of $90 million. However, this estimate is likely to under ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
New generation of catheters for treatment of atrial fibrillation
SBC: LUXMED SYSTEMS INC Topic: NHLBIABSTRACT Atrial fibrillation (AF) remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity and mortality primarily due to poor hemodynamic performance and often stroke. One of the primary options to treat AF is cardiac ablation where the physician applies radiofrequency energy via percutaneous catheters to form a series of ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health